Compare Amphastar Pharmaceuticals Inc (AMPH) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while United Microelectronics Corp trades at $23.93 (market cap $61.20B). The key difference: United Microelectronics Corp is far larger — about 74.1× Amphastar Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 1.69% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | UMC | |
|---|---|---|
Market Cap | $826.08M | $61.20B |
Sector | Health | Technology |
52-Week High | $30.81 | $28.02 |
52-Week Low | $16.87 | $6.58 |
Enterprise Value | $1.22B | $58.77B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
UMC trades at $24.34, down 2.09% today, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $237.55B in 2025, though net income margin compressed to 16.99%. Recent June 2026 sales rose 22.85% year-over-year, and the company launched a 14nm eHV FinFET platform for display drivers. Analyst consensus is mixed with 27% buy ratings, while institutional sentiment leans positive amid AI and automotive chip demand.
Outlook: UMC benefits from specialty semiconductor demand, but high P/E of 39.52 and margin pressures pose valuation risks. Earnings beats and dividend payments support income investors, yet competition and cyclical industry volatility require caution for growth-focused shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
